 |
 |
| 5-Year Data |
|
|
See the results of the longest reported controlled clinical study of male pattern hair loss. |
|
|
| View study results. |
|
 |
 |
|
|
|
|
|
 |
|
|
Clinical studies showed: |
|
|
|
|
Effect on the plasma lipid profile |
NO |
|
|
|
|
Negative effect on bone mineral density |
NO |
|
|
|
|
Blocking of or binding to the androgen receptor |
NO |
|
|
|
|
Androgenic, antiandrogenic, estrogenic, antiestrogenic,
or progestational effects |
NO |
|
|
|
|
Clinically meaningful changes in luteinizing hormone or follicle-stimulating hormone |
NO |
|
|
|
|
Effect on the hypothalamic-pituitary-testicular axis |
NO |
|
|
|
 |
Clinical studies showed men treated with PROPECIA® (finasteride) had increased mean testosterone and estradiol levels (approximately 15%), but these levels were within normal physiologic range. |
|
|
Important Information About PROPECIA
- Caution should be used in patients with liver function abnormalities, as finasteride is metabolized extensively in the liver.
- Physicians should instruct their patients to promptly report any changes in their breasts such as lumps, pain, or nipple discharge. Breast changes including breast enlargement, tenderness, and neoplasm have been reported.
- In clinical studies with finasteride 1 mg in men aged 18 to 41, the mean value of serum prostate-specific antigen (PSA) decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12. In clinical studies with PROSCAR® (finasteride 5 mg)* when used in older men who have benign prostatic hyperplasia (BPH), PSA levels are decreased by approximately 50%. These findings should be taken into account for proper interpretation of serum PSA when evaluating men treated with finasteride.
- No drug interactions of clinical importance have been identified.
| — |
Compounds that have been tested in men include antipyrine, digoxin, propranolol, theophylline, and warfarin, and no clinically meaningful interactions were found. |
|
|
|
Not an Antiandrogen
